AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
November 12, 2024 4:24 PM EST
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $362.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "When has three patients worth of data ever been the 'be all and end all'? Context matters, and while this MariTide data... More
November 12, 2024 4:23 PM EST
Barclays analyst Carter Gould reiterated an Equalweight rating and $315.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "We reviewed the supplemental MariTide (AMG133) phase 1 data, highlighted by (1) BMD loss (as measured by DEXA scan across femur and hip) at higher doses (420mg), and (2) notable heart rate excursions (25bpm at the 280mg dose). While far from... More
November 12, 2024 3:44 PM EST
Jefferies analyst Michael Yee reiterated a Buy rating and $380.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "We reviewed public data from Phase I AMG-133 showing add'l measurements of BMD (bone density) from obesity pts - which could be interpreted... More
November 12, 2024 2:48 PM EST
Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $405.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "We just came across a new piece of information from MariTide's Ph1, and we found a big surprise... The supplemental appendix file seems to show bone mineral... More
